Clinical Trials

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer


Study ID
Seattle Genetics SGN22E-002

NCT Number
NCT03288545 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0512

Principle Investigator
Dr. Robert Alter

Phase
I

Sponsor
Seattle Genetics


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now